Simvastatin increases the in vivo activity of the first-line tuberculosis regimen

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2453-2457

  Skerry, Ciaran ^a   Pinn, Michael L ^a   Bruiners, Natalie ^b   Pine, Richard ^b   Gennaro, Maria L ^b   Karakousis, Petros C ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Lipids; Mice; Statins; TB

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; SIMVASTATIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TUBERCULOSIS; WILD TYPE; ANIMAL; BACTERIAL COUNT; BAGG ALBINO MOUSE; CELL LINE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; LUNG; MICROBIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; CELL LINE; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; ISONIAZID; LUNG; MACROPHAGES; MICE, INBRED BALB C; PYRAZINAMIDE; RIFAMPIN; SIMVASTATIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84905992315     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku166     Document Type: Article

References (19)

1. Van Den Boogaard J, Kibiki GS, Kisanga ER et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009; 53: 849-62.
2. Gardner CA, Acharya T, Pablos-Méndez A. The global alliance for tuberculosis drug development-accomplishments and future directions. Clin Chest Med 2005; 26: 341-7.
3. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis. Am J Respir Crit Care Med 2001; 163: 1055-8.
4. Skerry C, Harper J, Klunk M et al. Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB granulomas. PLoS One 2012; 7: e39680.
5. Koo MS, Manca C, Yang G et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One 2011; 6: e17091.
6. Gupta S, Cohen KA, Winglee K et al. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 574-6.
7. Tleyjeh IM, Kashour T, Hakim FA et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-67.
8. Schmidt H, Hennen R, Keller A et al. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med 2006; 32: 1248-51.
9. Catron DM, Lange Y, Borensztajn J et al. Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation. Infect Immun 2004; 72: 1036-42.
10. Erkkila L, Jauhiainen M, Laitinen K et al. Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother 2005; 49: 3959-62.
11. Daniel J, Maamar H, Deb C et al. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog 2011; 7: e1002093.
12. Mahajan S, Dkhar HK, Chandra V et al. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARgamma and TR4 for survival. J Immunol 2012; 188: 5593-603.
13. Singh V, Jamwal S, Jain R et al. Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. Cell Host Microbe 2012; 12: 669-81.
14. Parihar SP, Guler R, Khutlang R et al. Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 2014; 209: 754-63.
15. Podechard N, Le Ferrec E, Rebillard A et al. NPC1 repression contributes to lipid accumulation in human macrophages exposed to environmental aryl hydrocarbons. Cardiovasc Res 2009; 82: 361-70.
16. Ahmad Z, Fraig MM, Pinn ML et al. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother 2011; 66: 1560-6.
17. Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab 2009; 94: 2489-94.
18. Subbian S, Tsenova L, O'Brien P et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 2011; 7: e1002262.
19. Peyron P, Vaubourgeix J, Poquet Y et al. Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 2008; 4: e1000204.